To compare the effectiveness of GT on the CDD-related phenotype in hemizygous Cdkl5 KO males and heterozygous Cdkl5 +/− females, we employed the same viral dose (1012 vg/mouse), and route of administration (systemic, via intracarotid injection) established in our previous work [21]. Here, CDKL5 is linked to craniodiaphyseal dysplasia.